



# Cibinqo in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

IMMUNOLOGY · MODERATE-TO-SEVERE ATOPIC DERMATITIS

## The clinical situation

Cibinqo (abrocitinib) is an oral, once-daily selective JAK1 inhibitor FDA-approved for adults with moderate-to-severe atopic dermatitis inadequately controlled by systemic therapies or when those are not advisable. Manufactured by Pfizer. Dosing is 100 mg or 200 mg once daily per labeling. Pre-treatment workup covers TB, hepatitis B/C, lipid panel, CBC, and LFTs. The FDA JAK-class boxed warning on serious infections, malignancy, MACE, and thrombosis applies; your dermatologist performs the risk-benefit assessment.

## The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your dermatologist documents AD severity (EASI, IGA, itch NRS), prior systemic therapy history, and Cibinqo rationale.
- 2 Baseline screening.** TB, viral hepatitis, lipid panel, CBC, LFTs, and vaccination status are completed and documented per FDA labeling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, strength, quantity, and chain-of-custody plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with tamper-evident international shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; your dermatologist initiates therapy with ongoing JAK-class monitoring.

## Indicative economics

**Reference US cash-pay range:** USD 6,000–7,000 per 30-tablet month supply of Cibinqo (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

## Indicative first-dose timing

**7–14 days** from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody from Pfizer authorised distribution.

**Documentation.** Physician kit tailored to SFDA review, with JAK-class cardiovascular and malignancy annex. **Logistics.**

Tamper-evident, internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through the case arc. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Cibinqo × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/cibinqo-saudi-arabia.html](https://reservemed.com/access-guides/cibinqo-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team